Characteristics of acute care trials
| Acute care trial characteristics | No of trials (%) |
| Type of trial | |
| Intensive care | 75 (85.2) |
| Cardiology | 13 (14.8) |
| No of participants | |
| ≤250 | 15 (17) |
| 251–500 | 17 (19.3) |
| 501–1000 | 23 (26.1) |
| 1001–3000 | 24 (27.3) |
| ≥3001 | 9 (10.2) |
| No of centres | |
| Multicentre | 83 (94.3) |
| Single centre | 5 (5.7) |
| Continent of origin | |
| Europe | 49 (55.7) |
| North America | 24 (27.3) |
| Oceania/Australia | 7 (7.9) |
| Asia | 4 (4.6) |
| South America | 4 (4.6) |
| Year of publication | |
| 2014 | 26 (29.6) |
| 2018 | 32 (36.4) |
| 2020 | 30 (34.1) |
| Journal | |
| New England Journal of Medicine | 35 (39.8) |
| Journal of the American Medical Association | 35 (39.8) |
| The Lancet | 17 (19.3) |
| British Medical Journal | 1 (1.1) |
| Annals of Internal Medicine | 0 (0) |
| Trial population | |
| Cardiovascular | 24 (27.3) |
| Neurologic | 22 (25.0) |
| Respiratory | 18 (20.5) |
| Infectious disease | 11 (12.5) |
| Gastrointestinal | 6 (6.8) |
| Renal | 5 (5.7) |
| Musculoskeletal | 1 (1.1) |
| Endocrine | 1 (1.1) |
| Type of intervention | |
| Pharmacologic | 50 (56.8) |
| Non-pharmacologic | 36 (40.9) |
| Pharmacologic and non-pharmacologic | 2 (2.3) |